GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
News 28.05.2025 Newton, MA & Wädenswil, Switzerland – May 27, 2025– GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, today announced the closing of an oversubscribed $130 million Series B financing. The proceeds will be used to advance the Company’s lead IgG4-targeted protein degrader...